KARLAVAGEN 100, 115 26, STOCKHOLM, V7
Shareholder votes
Reports 2025 Financial Results
Reports Quarter Ended September 30, 2025 Financial Results
Announces Anticipated Financial Proceeds from Patent Lawsuit Settlement
Reports Quarter Ended June 30, 2025 Financial Results
Announces Adjournment of Reconvened Annual Meeting of Stockholders
Announces Adjournment of Annual Meeting of Stockholders
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence
Definitive Revised Proxy Statement